## Accepted Manuscript

Title: Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

Authors: Lvan Andel, H. Rosing, R. Lubomirov, P. Avilés, S. Fudio, M.M. Tibben, L. Nan-Offeringa, J.H.M. Schellens, J.H. Beijnen



PII:	\$0731-7085(18)31176-2
DOI:	https://doi.org/10.1016/j.jpba.2018.05.053
Reference:	PBA 12004
To appear in:	Journal of Pharmaceutical and Biomedical Analysis
Received date:	17-5-2018
Accepted date:	31-5-2018

Please cite this article as: Lvan Andel, H.Rosing, R.Lubomirov, P.Avilés, S.Fudio, M.M.Tibben, L.Nan-Offeringa, J.H.M.Schellens, J.H.Beijnen, Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine, Journal of Pharmaceutical and Biomedical Analysis https://doi.org/10.1016/j.jpba.2018.05.053

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

### **Short communication**

## Development and validation of a liquid chromatographytandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

L van Andel<sup>1,2\*</sup>, H Rosing<sup>1</sup>, R Lubomirov<sup>3</sup>, P Avilés<sup>3</sup>, S Fudio<sup>3</sup>, MM Tibben<sup>1</sup>, L Nan-Offeringa<sup>1</sup>, JHM Schellens<sup>2,4,5</sup>, JH Beijnen<sup>1,2,5</sup>

#### Authors' affiliations:

<sup>1</sup>Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek / The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands;

<sup>2</sup>Division of Pharmacology, Antoni van Leeuwenhoek / The Netherlands Cancer Institute, Amsterdam, The Netherlands;

<sup>3</sup>Pharma Mar, S.A. Colmenar Viejo, Madrid, Spain;

<sup>4</sup>Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

<sup>5</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

\***Corresponding author**: Lotte van Andel, MSc, Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek hospital and MC Slotervaart, Amsterdam, the Netherlands, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands. Telephone: +31 20 512 9086, E-mail: <u>l.v.andel@nki.nl</u>

Article type: short communication Words (title, authors, article, references): 2848 Figures and tables: 5 Download English Version:

# https://daneshyari.com/en/article/7626185

Download Persian Version:

https://daneshyari.com/article/7626185

Daneshyari.com